Crescita Therapeutics Inc.
CRRTF
$0.56
$0.00-0.85%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.05M | 4.27M | 3.92M | 4.51M | 2.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.05M | 4.27M | 3.92M | 4.51M | 2.46M |
| Cost of Revenue | 2.15M | 2.35M | 1.84M | 1.74M | 1.37M |
| Gross Profit | 1.90M | 1.92M | 2.07M | 2.76M | 1.09M |
| SG&A Expenses | 2.53M | 2.33M | 1.81M | 1.99M | 1.62M |
| Depreciation & Amortization | 140.20K | -253.90K | 278.80K | 255.10K | 122.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.92M | 4.54M | 4.03M | 4.08M | 3.20M |
| Operating Income | -866.50K | -273.30K | -117.60K | 421.40K | -740.00K |
| Income Before Tax | -834.10K | -503.50K | 546.70K | 576.80K | -649.40K |
| Income Tax Expenses | -- | 6.50K | -- | -- | -- |
| Earnings from Continuing Operations | -834.10K | -510.00K | 546.70K | 576.80K | -649.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -834.10K | -510.00K | 546.70K | 576.80K | -649.40K |
| EBIT | -866.50K | -273.30K | -117.60K | 421.40K | -740.00K |
| EBITDA | -588.20K | -82.10K | 161.20K | 676.50K | -494.00K |
| EPS Basic | -0.04 | -0.03 | 0.03 | 0.03 | -0.03 |
| Normalized Basic EPS | -0.03 | 0.00 | 0.02 | 0.02 | -0.02 |
| EPS Diluted | -0.04 | -0.03 | 0.03 | 0.03 | -0.03 |
| Normalized Diluted EPS | -0.03 | 0.00 | 0.02 | 0.02 | -0.02 |
| Average Basic Shares Outstanding | 18.61M | 18.61M | 18.84M | 18.93M | 19.03M |
| Average Diluted Shares Outstanding | 18.61M | 18.61M | 18.85M | 19.04M | 19.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |